Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Min-hui Wang"'
Autor:
Chang-Ming Chen, Qiu-Long Yan, Ruo-Chun Guo, Fang Tang, Min-Hui Wang, Han-Zhi Yi, Chun-Xia Huang, Can Liu, Qiu-Yi Wang, Wei-Ya Lan, Zong Jiang, Yu-Zheng Yang, Guang-Yang Wang, Ai-Qin Zhang, Jie Ma, Yan Zhang, Wei You, Hayan Ullah, Yue Zhang, Sheng-Hui Li, Xue-Ming Yao, Wen Sun, Wu-Kai Ma
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background/purpose(s) The gut microbiota and its metabolites play crucial roles in pathogenesis of arthritis, highlighting gut microbiota as a promising avenue for modulating autoimmunity. However, the characterization of the gut virome in a
Externí odkaz:
https://doaj.org/article/e24c7e34b4854088bf25dbdb4985a91d
Publikováno v:
BMC Nursing, Vol 22, Iss 1, Pp 1-7 (2023)
Abstract Background Coronary heart disease (CHD) is a cardiovascular disease with high mortality. At present, percutaneous coronary intervention (PCI) is considered as the main effective treatment for CHD due to less trauma, shorter course of treatme
Externí odkaz:
https://doaj.org/article/e5ad4c8930d24931b188b36ed2d5a52a
Publikováno v:
The Scientific World Journal, Vol 2014 (2014)
Background and Objectives. Hyperparathyroidism and hyperphosphatemia contribute to the inflammatory effects in chronic hemodialysis (HD) patients. Interleukin-17-producing CD4+ effector memory T (Th17) cells and CD4+CD25+Foxp3 regulatory T (Treg) cel
Externí odkaz:
https://doaj.org/article/ff41802b2bfc4699acb04590d0311511
Autor:
Paolo Ghia, Andrzej Pluta, Małgorzata Wach, Daniel Lysak, Martin Šimkovič, Iryna Kriachok, Árpád Illés, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Ganna Usenko, Min Hui Wang, Ting Yu, Wojciech Jurczak
Publikováno v:
HemaSphere, Vol 6, Iss 12, p e801 (2022)
Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia (CLL). ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator’s choice of idelalisib plus rituximab (IdR) or bendamustine
Externí odkaz:
https://doaj.org/article/8861f967d3964d909ede74df166018f2
Autor:
Min-Hui Wang, 王銘輝
101
A simulation program was developed to provide the functions of zoom in and zoom out to view the photos in different scale which is similar to the Google Maps. The developed program was applied to the education of the nanotechnology to provid
A simulation program was developed to provide the functions of zoom in and zoom out to view the photos in different scale which is similar to the Google Maps. The developed program was applied to the education of the nanotechnology to provid
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/20208852003937315608
Autor:
John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O'Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Piers EM Patten, Talha Munir, Krish Patel, Anna Butturini, Marianne de Borja, Min Hui Wang, Nitin Jain, William G. Wierda
Publikováno v:
Blood. 140:9865-9867
Autor:
Richard R. Furman, William G. Wierda, Anna Schuh, Piers EM Patten, Jorge M. Chaves, Jennifer R. Brown, Talha Munir, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, Krish Patel, Jennifer A. Woyach, Anna Butturini, Marianne de Borja, Min Hui Wang, Susan O'Brien, John C. Byrd
Publikováno v:
Blood. 140:9873-9875
Autor:
John C. Byrd, Min-Hui Wang, Cheng Quah, Veerendra Munugalavadla, Raquel Izumi, Ahmed Hamdy, Melanie M. Frigault, Michael Gulrajani, Barbara L. Andersen, David M. Weiss, Gerard Lozanski, Mojgan Jianfar, Seema A. Bhat, Kerry A. Rogers, James S. Blachly, Jennifer A. Woyach
Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba6e8b6c08b1eaaf021847b37b47834a
https://doi.org/10.1158/2159-8290.c.6547811.v1
https://doi.org/10.1158/2159-8290.c.6547811.v1
Autor:
John C. Byrd, Min-Hui Wang, Cheng Quah, Veerendra Munugalavadla, Raquel Izumi, Ahmed Hamdy, Melanie M. Frigault, Michael Gulrajani, Barbara L. Andersen, David M. Weiss, Gerard Lozanski, Mojgan Jianfar, Seema A. Bhat, Kerry A. Rogers, James S. Blachly, Jennifer A. Woyach
Figure S1 shows immunoglobulin A, B, and M levels in treated patients over time Figure S2 shows investigator-assessed progression-free survival by CLL-IPI score and presence or absence of complex karyotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ecbd95eea50dde789f03387b686897
https://doi.org/10.1158/2159-8290.22535279.v1
https://doi.org/10.1158/2159-8290.22535279.v1
Autor:
Priti Patel, Peter Hillmen, Raquel Izumi, William G. Wierda, Jean Cheung, Paolo Ghia, Anna Schuh, Toby A. Eyre, John M. Pagel, Richard R. Furman, Min Hui Wang, Jennifer R. Brown, John C. Byrd, Ahmed Hamdy, Yan Xu
Publikováno v:
The Lancet Haematology. 8:e912-e921
Summary Background Patients with chronic lymphocytic leukaemia who progress to Richter transformation (diffuse large B-cell lymphoma morphology) have few therapeutic options. We analysed data from the Richter transformation cohort of a larger, ongoin